Anti-Enteric Neuronal Antibodies and the Irritable Bowel Syndrome

Jackie D Wood,1* Sumei Liu,2 Douglas A Drossman,3 Yehuda Ringel3 and William E Whitehead3

1Department of Physiology and Cell Biology, The Ohio State University Medical Center, Columbus, Ohio, USA; 2Department of Biology, University of Wisconsin-La Crosse, Lacrosse, Wisconsin, USA; and 3Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

Background/Aims
Functional gastrointestinal disorders are those in which no abnormal metabolic or physical processes, which can account for the symptoms, can be identified. The irritable bowel syndrome (IBS) is a significant functional disorder, which affects 10-20 percent of the population worldwide. Predominant symptoms of IBS are abnormal defecation associated with abdominal pain, both of which may be exacerbated by psychogenic stress. Our study was designed to test a hypothesis that symptoms in a subset of patients with a diagnosis of IBS are associated with an autoimmune degenerative neuropathy in the enteric nervous system.

Methods
Serum was collected from Rome II-IBS patients and controls at the University of North Carolina Functional Gastrointestinal Diseases Center. Assay procedures were immunohistochemical localization of antibody binding to enteric neurons and human protein microarray assay for antigens recognized by antibodies in the sera.

Results
Eighty-seven percent of IBS sera and 59% of control sera contained anti-enteric neuronal antibodies. Antibody immunostaining was seen in the nucleus and cytoplasm of neurons in the enteric nervous system. Protein microarray analysis detected antibody reactivity for autoantigens in serum with anti-enteric neuronal antibodies and no reactivity for the same autoantigens in samples not containing anti-enteric neuronal antibodies in our immunostaining assay. Antibodies in sera from IBS patients recognized only 3 antigens out of an 8,000 immunoprotein array. The 3 antigens were: (1) a nondescript ribonucleoprotein (RNP-complex); (2) small nuclear ribonuclear polypeptide A; and (3) Ro-5,200 kDa.

Conclusions
Results of the present study suggest that symptoms in a subset of IBS patients might be a reflection of enteric neuronal damage or loss, caused by circulating anti-enteric autoimmune antibodies.

(J Neurogastroenterol Motil 2012;18:78-85)

Key Words
Autoimmune neuropathy; Enteric nervous system; Gastrointestinal disorders
Introduction

The irritable bowel syndrome (IBS) is a functional gastrointestinal disorder (FGID). IBS diminishes quality of life for 8%-20% of populations worldwide. Predominant symptoms of IBS are abnormal defecation associated with abdominal pain, both of which may be exacerbated by psychogenic stress.

A disordered enteric nervous system (ENS) might underlie some forms of IBS pathophysiology. Activity of the musculature, glands and vascular system to generate functionally effective patterns of behavior, which are adaptive for differing digestive states, is controlled by the ENS. The gut does not work without the ENS. This is apparent in its absence in terminal regions of the large intestine in Hirschsprung’s disease. Autoimmune ablation of the ENS in the lower esophageal sphincter underlies the pathophysiology of achalasia. Neuropathic degeneration of ENS neurons in IBS, gastrointestinal (GI) pseudoobstruction, Chagas disease, paraneoplastic syndrome and enteric ganglionitis, underlies the morbidity. Progressive degenerative loss of neurons from the ENS neural networks is reminiscent of dropout of dopaminergic neurons in Parkinson disease where gradual depletion advances from minor symptoms to severe stages of somatic motor dysfunction. Progressive loss and degradation of ENS control of the gut musculature, glands and vasculature is expected to be likewise manifest as steady worsening of gut-related symptoms.

Retrospective review suggests that IBS-like symptoms in a subgroup of patients might be an expression of early stages of a progressive degenerative ENS neuropathy that culminates as intestinal pseudoobstruction when neuronal loss reaches levels that compromise ENS programing of propulsive motility. This is reminiscent of chronic GI pseudoobstruction in paraneoplastic syndrome where commonality of antigens between certain cancer cells (eg, small-cell lung carcinoma) and ENS neurons leads to autoimmune attack that destroys the neurons. Patients with symptoms of pseudoobstruction in combination with small-cell lung carcinoma express IgG autoantibodies that bind to ENS neurons in the stomach and small intestine. This damages, destroys and removes the neurons from the integrative neural networks through induction of apoptosis.

We aimed to evaluate the prevalence of anti-enteric neuronal antibodies in patients diagnosed with idiopathic IBS according to Rome II symptom-based criteria. Our approach was based on one used productively by others for evaluation of anti-enteric neuronal antibodies in patients with the paraneoplastic syndrome. Some of the results have appeared in abstract form.

Materials and Methods

Blood was drawn from 78 IBS patients and 22 controls in the Center for Functional GI and Motility Disorders at the University of North Carolina, Chapel Hill (UNC). Each patient reported symptoms of abdominal pain a minimum of 25% of the time in the last 3 months and met Rome II criteria for IBS as confirmed by UNC clinical gastroenterologists. The controls,
which were recruited from the UNC gastroenterology unit and by public advertising, reported no significant recurring GI symptoms. The study was approved by the UNC institutional review board and all subjects provided written informed consent.

Sera were separated, coded at UNC and transported frozen to The Ohio State University. Each sample was tested, in blinded manner, for presence of anti-enteric neuronal antibodies. The protocol consisted of incubation of whole-mount preparations of guinea pig ENS with patient or control sera followed by fluorescent immunohistochemistry to visualize antibodies that recognized ENS neurons (Fig. 1).

Whole-mount ENS preparations were obtained from male albino Hartley guinea pigs. The guinea pigs were killed by stunning and exsanguination as approved by The Ohio State University ILAUC (Protocol 2010A0023; approved 2/11/2010; expiration 2/11/2013). The small intestine was removed, immediately flushed with ice-cold Krebs solution and divided into segments that were fixed overnight in Zamboni’s fixative. Microdissection was used to prepare whole-mount preparations of the myenteric and submucosal plexuses for immunohistochemistry (Fig. 1A).

Whole-mount preparations were used for indirect immunofluorescence screening for the presence of anti-enteric neuronal antibodies in the samples. The preparations were placed in phosphate buffered saline (PBS) containing 10% normal donkey serum and 0.3% Triton X-100 for 30 minutes at room temperature followed by incubation in a serum sample overnight at room temperature. This was followed by washing the tissue in PBS and incubation in indocarbocyanin (Cy3)-labeled donkey anti-human IgG (1:500) at room temperature for 1 hour. The tissues were then washed in PBS and cover slipped with Vectashield® mounting medium (Vector lab, Burlingame, CA, USA). Fluorescent labeling was viewed with a Nikon Eclipse 90i fluorescence microscope (Nikon, Tokyo, Japan) and analyzed with filter combinations that enabled separate visualization of multiple fluorophores. Photomicrographs were acquired with a CoolSnap HQ2 monochrome digital camera (Roper Scientific, Tucson, AZ, USA), stored on disk and analyzed with MetaMorph® software (MetaMorph, Carl Zeiss Meditec, Göttingen, Germany). Specificity of labeling of ENS neurons by antibodies in the serum samples was verified by pre-absorbing antibodies in the sample with a liver substrate (100 mg/mL; Sigma-Aldrich, St. Louis, MO, USA) and finding no differences in immunostaining for serum exposed or not exposed to liver substrate. Whole sections of liver or kidney were exposed to serum samples that produced intense neuronal staining and examined for fluorescent staining as an added control for specificity.

Serum samples were screened initially at a dilution of 1:50. When immunoreactivity was found, stepwise doubling of dilutions was done until no staining above background was evident. The final dilution that yielded staining above background was recorded as the antibody titer. Samples were scored blindly by 3 experienced ENS histologists with a semiquantitative rating scale where: “0” = no neuronal fluorescent staining above background; “1” = moderate intensity of fluorescent staining; and “2” = intense fluorescent staining. Background staining was defined as that produced when the secondary anti-human IgG antibody alone was applied.

Two-way contingency tables were generated with frequency, percentage, row percentage and column percentage. Fisher’s exact test was used to test associations between 2 category variables. A P-value < 0.05 represented statistical significance in hypothesis testing.

The serum samples were analyzed with Invitrogen ProtoArray® human protein microarray immune response biomarker profiling kit (Cat. PAH0525102; Invitrogen, Carlsbad, CA, USA). Serum samples, which were determined to contain anti-enteric neuronal antibodies by immunostaining assay, were coded and compared blindly with a coded set that did not contain antibody immunoreactivity in the assay. We used Invitrogen’s ProtoArray® human protein microarray v4.1 immune response biomarker profiling kit (Invitrogen), which screens for 8,000 unique proteins associated with the human immunoglobulin lambda locus. This locus is a region on chromosome 22 that contains genes for lambda antibody light chains.

ProtoArray data were analyzed with ProtoArray® Prospector v5.0 (Invitrogen). This is a freeware software program from Invitrogen™ designed for identification of antibodies on the ProtoArray® microarray that are bound by extrinsic antibodies applied as a mixture of antibodies in a serum sample. ProtoArray® Prospector analyzes results where any bound antibody in the sample is detected by probing with a second fluorescently-labeled, IgG class-specific antibody. Binding of the second antibody on the microarray is then quantified by measuring the fluorescence intensity of each spot on the microarray profile. Values (Z-factors) for the fluorescent signals are calculated by taking into account corrections for background and negative controls on the microarray. The program identifies signals that have Z-factors greater than a user-defined cut-off; the cut-off was set at 0.4. Z-factors > 0.4 were scored as positive “hits”. The program nor-
Anti-enteric autoimmune neuropathy was revealed as fluorescent staining of neuronal cell bodies following incubation with patients’ serum. The fluorescence was emitted from anti-human IgG antibodies, which were bound to anti-enteric neuronal antibodies in the serum, which in turn, were bound to antigens expressed by the neurons (Fig. 1). When anti-enteric neuronal antibodies were present, double labeling with an antibody against the pan-neuronal marker HuC/D showed neurons to be the only cell type recognized by the antibodies (Fig. 2A and 2B). Sera from 78 IBS patients and 22 controls were examined. The patients were categorized as diarrhea predom-

**Figure 2.** Anti-enteric neuronal antibodies in serum from irritable bowel syndrome patient GCRC 2115. (A) Ganglion in the myenteric plexus stained with fluorescently-labeled anti-human IgG following incubation with patient’s serum. Antibodies in the serum reacted with virtually all ganglion cells. Reaction is restricted to ganglion cell nuclei for this case. (B) The same ganglion stained with anti-human neuronal protein HuC/D, which identifies all neuronal cell bodies in the ganglion. Anti-HuC/D immunoreactivity was expressed in the nucleus and cytoplasm and therefore outlined the entire cell body. (C) Digital merger of patient’s antibody staining and anti-Hu. IBS, irritable bowel syndrome.

**Table 1.** Results for Irritable Bowel Syndrome Patients and Controls With or Without Anti-Enteric Neuronal Antibodies

|                      | Patients (n = 76) | Controls (n = 22) |
|----------------------|------------------|------------------|
|                      | IBS-C | IBS-D | IBS-A/M |        |
| Sex (n [%])          |        |        |        |        |
| Female               | 6 (7.9)| 15 (19.7)| 34 (44.7)| 22 (100) |
| Male                 | 1 (1.3)| 6 (7.9) | 14 (18.4)| -         |
| Age (mean ± SD, yr)  |        |        |        |        |
| Female               | 36.5 ± 12.0| 30.9 ± 10.0| 32.4 ± 12.6| 39.6 ± 14.8 |
| Male                 | 32.0 ± 00.0| 38.5 ± 6.2 | 31.6 ± 10.0| -         |
| Stain (n)            |        |        |        |        |
| Female               | 0      | 2      | 2      | 4       |
|                      | 1      | 4      | 10     | 23      |
|                      | 2      | 0      | 3      | 7       |
| Male                 | 0      | 0      | 1      | 3       |
|                      | 1      | 0      | 4      | 8       |
|                      | 2      | 1      | 1      | 3       |

Immunostain intensity was scored as 0 = no staining, 1 = moderate staining and 2 = intense staining for myenteric neurons. Mean stain intensity derived from scores entered by 3 observers. IBS-C, constipation predominant IBS; IBS-D, diarrhea predominant IBS; IBS-A/M, alternating/mixed IBS.
Table 2. Results Obtained With Invitrogen, Inc. Immune Response Biomarker Profiling Assay

| Protein name                        | IBS-A signal (density) | IBS-B signal (density) | IBS-A Z-score (hit) | IBS-B Z-factor (hit) |
|-------------------------------------|------------------------|------------------------|---------------------|---------------------|
| Ribonucleoprotein complex           | 56,544.5               | 184                    | 51.727              | 0.072               | 0.895               | -6.286              | 1              | 1 |
| Small nuclear ribonuclear polypeptide A | 7,530                  | 49                     | 6.783               | 0.404               | 0.807               | -7.820              | 1              | 0 |
| Anti-Ro 5,200 MW                    | 254,043.5              | 338.5                  | 22.843              | 0.239               | 0.775               | -6.494              | 1              | 0 |

IBS, irritable bowel syndrome; IBS-A, serum samples with anti-enteric neuronal antibodies; IBS-B, serum samples without anti-enteric neuronal antibodies. Three blinded samples known to contain anti-enteric neuronal antibodies in immunostain assays (IBS-A) and 3 samples without antibodies in immunostain assays (IBS-B) were pooled. Out of 8,000 possibilities, 3 antigens were identified as reacting with antibodies in the IBS-A sera. No "hits" were obtained with IBS-B sera. The 3 identified antigens ("hits") in IBS-A sera consisted of a nondescript ribonucleoprotein complex, Anti-Ro 52,000 MW and small nuclear ribonucleoprotein polypeptide A.
activity for the same autoantigens was found in serum samples that did not contain the antibodies in our immunostain assay. Antibody titers for a nondescript macromolecular complex containing both protein and RNA molecules (ie, ribonucleoprotein complex) and small ribonuclear polypeptide A were present in high titers in the same sera that contained anti-enteric neuronal antibodies in our neuronal assays. Moderate levels of anti-Ro 52,000 MW antibody were present also in antibody-containing IBS sera and not in sera devoid of antibodies in immunostain assays (Table 2).

Discussion

Three outcomes are noteworthy in terms of the etiopathogenesis of IBS and FGIDs: (1) Anti-enteric neuronal antibodies, present in sera from IBS patients, suggest that an autoimmune degenerative neuropathy in the ENS might underlie their symptoms, (2) The high proportion of IBS patients with the antibodies in their blood (84.2%) is unexpectedly high and suggests that autoimmune damage and loss of neurons in the ENS might be an important factor underlying their symptoms and (3) The anti-enteric neuronal antibodies in IBS are directed only to three previously unrecognized kinds of antigens expressed by ENS neurons and no other cell type in the intestine.

Anti-enteric neuronal antibodies in the IBS patients in our study are reminiscent of paraneoplastic neurological disease. Disordered gut motility associated with the paraneoplastic syndrome is explained as due to commonality of antigens between some cancers (eg, small-cell lung carcinoma) and ENS neurons. Antibody recognition of the antigens underlies the autoimmune attack, which results in decimation of neurons that form the ENS integrative circuitry. The antibodies, after binding, induce apoptosis in guinea pig ENS neurons. Apoptosis in ENS neurons involves mitochondrial events as indicated by specific activation of effector caspase-3 and the cytochrome C-dependent proapoptotic messenger apaf-1. The neuronal autoantibody commonly associated with paraneoplastic dysmotility in the gut is the Type-1 anti-neuronal nuclear antibody. This antibody binds to the nuclear protein Hu, which is part of a family of conserved RNA-binding proteins that includes HuC, HuD and HuR. These proteins are expressed in neurons of the ENS as well as other autonomic ganglia, sensory neurons and the central nervous system (Fig. 2B).
References

1. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-1390.

2. Ringel Y, Sperber AD, Drossman DA. Irritable bowel syndrome. Ann Rev Med 2001;52:319-338.

3. Gwee KA, Wee S, Wong ML, Pang DJ. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community. Am J Gastroenterol 2004;99:924-931.

4. Pan G, Lu S, Ke M, Han S, Guo H, Fang X. Epidemiologic study of the irritable bowel syndrome in Beijing: stratified randomized study by cluster sampling. Chin Med J (Engl) 2000;113:35-39.

5. Quigley EM. Changing face of irritable bowel syndrome. World J Gastroenterol 2006;12:1-5.

6. Thompson WG, Longstreth GL, Drossman DA, Heaton K, Irvine EJ, Muller-lissner S. Functional bowel disorders and functional abdominal pain. In: Drossman DA, Corazziari E, Talley NJ, Ghorbachi S, editors. Rome II: The functional gastrointestinal disorders. 2nd ed. McLean: Degnon Associates 2000: 351-432.

7. Wood JD. Pathophysiology underlying the irritable bowel syndrome. In: Johnson LR, Barrett KE, Ghoshan FK, Merchant JL, Said HM, Wood JD, eds. Physiology of the gastrointestinal tract. 4th ed. San Diego: Academic Press 2006:1009-1031.

8. Wood JD. Neuropathophysiology of functional gastrointestinal disorders. World J Gastroenterol 2007;13:1313-1332.

9. Knowles CH. New horizons in the pathogenesis of gastrointestinal neuromuscular disease. J Pediatr Gastroenterol Nutr 2007;45(suppl 2):S97-S102.

10. Verne GN, Sallustio JE, Eaker EY. Anti-myenteric neuronal antibodies in patients with achalasia: A prospective study. Dig Dis Sci 1997;42:307-313.

11. Moses PL, Ellis LM, Anees MR, et al. Antineuronal antibodies in idiopathic achalasia and gastro-oesophageal reflux disease. Gut 2003;52:629-636.

12. Krishnamurthy S, Heng Y, Schuffler MD. Chronic intestinal pseudo-obstruction in infants and children caused by diverse abnormalities of the myenteric plexus. Gastroenterology 1993;104:1398-1408.

13. De Giorgio R, Barbara G, Stanghellini V, et al. Clinical and morpho-functional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. Am J Gastroenterol 2002;97:2454-2459.

14. De Giorgio R, Bovara M, Barbara G, et al. Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology 2003;125:70-79.

15. De Giorgio R, Guerini S, Barbara G, Cremon C, Stanghellini V, Corinaldesi R. New insights into human enteric neuropathies. Neurogastroenterol Motil 2004;16(suppl 1):143-147.

16. De Giorgio R, Guerini S, Barbara G, et al. Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004;126:1872-1883.

17. De Giorgio R, Stanghellini V, Barbara G, et al. Primary enteric neuropathies underlying gastrointestinal motor dysfunction. Scand J Gastroenterol 2000;35:114-122.

18. Wood JD. Neuropathy in the brain-in-the-gut. Eur J Gastroenterol Hepatol 2000;12:397-600.

19. Törnblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002;123:1972-1979.

20. Linberg G, Törnblom H, Iwarson M, Nyberg B, Martin JE, Veress B. Full-thickness biopsy findings in chronic intestinal pseudo-obstruction and enteric dystrophy. Gut 2009;58:1084-1090.

21. Lemon VA, Sos DF, Busk MF, et al. Enteric neuronal autoantibodies in pseudodystrophy with small-cell lung carcinoma. Gastroenterology 1991;100:137-142.

22. Galanis E, Frytak S, Rowland KM Jr, Sloan JA, Lennon VA. Neuronal autoantibody titers in the course of small-cell lung carcinoma and platinum-associated neuropathy. Cancer Immunol Immunother 1999;48:85-90.

23. Nguyen-tat M, Pohl J, Günter E, et al. Severe paraneoplastic gastro-paresis associated with anti-Hu antibodies preceding the manifestation of small-cell lung cancer. Z Gastroenterol 2008;46:274-278.

24. Wood JD, Liu S, Ren W, Whitehead WE. Autoimmune degenerative neuropathy in the enteric nervous system (ENS) in functional gastrointestinal disorders (FGIDs). Gastroenterology 2010;138 (suppl 1):S586-S587.

25. Lin Z, Gao N, Hu HZ, et al. Immunoreactivity of Hu proteins facilitates identification of myenteric neurons in guinea-pig small intestine. Neurogastroenterol Motil 2002;14:197-204.

26. King PE, Redden D, Paluguen JS, Nabors LB, Lennon VA. Hu antigen specificities of ANNA-1 autoantibodies in paraneoplastic neurological disease. J Autoimmun 1999;13:435-443.

27. Schuffler MD, Baird HW, Fleming CR, et al. Intestinal pseudo-obstruction as the presenting manifestation of small-cell lung carcinoma. Gastroenterology 2003;125:70-79.

28. Corinaldesi R. New insights into human enteric neuropathies. J Autoimmun 1999;13:435-443.

29. Schuffler MD, Baird HW, Fleming CR, et al. Intestinal pseudo-obstruction as the presenting manifestation of small-cell lung carcinoma. Gastroenterology 2003;125:70-79.

30. Dropcho EJ. Remote neurologic manifestations of cancer. Neurol Clin 2002;20:85-122, vi.

31. Lennon VA. Calcium channel and related paraneoplastic disease autoantibodies. In: Peter JB, Shoenfeld Y, eds. Autoantibodies. Amsterdam: Elsevier 1996:139-146.

32. Ule J. Ribonucleoprotein complexes in neurologic diseases. Curr Opin Neurobiol 2008;18:516-521.

33. Lundberg I, Nyman U, Pettersson I, Hedfors E. Clinical manifest-
tations and anti-(U1)snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients. Br J Rheumatol 1992;31:811-817.

33. Nyman U, Lundberg I, Hedfors E, Pettersson I. Recombinant 70-kD protein used for determination of autoantigenic epitopes recognized by anti-RNP sera. Clin Exp Immunol 1990;81:52-58.

34. Ben-Chetrit E, Chan EKL, Sullivan KF, Tan EM. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. J Exp Med 1988;167:1560-1571.

35. Peene I, Meheus L, Veys EM, De Keyser F. Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of sera referred for ANA testing. Ann Rheum Dis 2001;60:1131-1136.

36. Parker JC, Burlingame RW, Bunn CC. Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis. J Autoimmune Dis 2009;6:2-7.